This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical efficacy of etanercept in adults

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A number of studies have been performed demonstrating the efficacy of etanercept.

In 180 adults a dose dependent fall in the number of involved joints was demonstrated after 3 months of treament. At the highest dose - 16mg/m2 - 64% improved, compared to 28% in the placebo group. Benefits manifested within 2 weeks, but symptoms returned a few weeks after stopping the drug.

In a study of 234 adults on etanercept 25mg, 62% had acheived a 20% improvement (ACR20 response), and 41% had acheived a 50% improvement (ACR50) by 3 months compared to placebo (23%). These improvements persisited at 6 months.

A study of 632 patients with disease duration of less than 3 years compared etanercept with methotrexate (mean dose 19mg). This study showed greater improvements in the etanercept group at 6 months and a year (using ACR-N). When measured using standard ACR response criteria (ACR 20,50,70) however results for etanercept were better than methotrexate at 6 months but not at one year.

A study of 89 patients with active disease despite methotrexate has also been performed. This showed that the addition of etanercept increased the number of those acheiveing a 20% response at 6 months from 27% to 71%.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.